Overview of Loratine

Quick Facts

Property	Description
Active Ingredient	Loratadine
Form	Tablet, Oral Syrup, Disintegrating Tablet
Pharmacological Class	Second-Generation Antihistamine
Common Use	Relief of general allergic conditions
Origin	Synthetic Compound (Tricyclic Piperidine derivative)

Loratine: Classification and Chemical Identity

Loratine is a medication formulated with the active ingredient Loratadine, which is classified as a second-generation antihistamine and a highly selective H₁-receptor antagonist. Its fundamental purpose is to modulate the body's response to histamine. Its chemical identity defines it as a synthetic compound—specifically a tricyclic piperidine derivative—that prevents histamine from triggering reactions in the body.

The classification as a second-generation compound reflects its design to minimize the central nervous system effects common to older antihistamines. Loratadine is the functional core, utilized globally under various trade names, reflecting its acceptance as a single-ingredient product manufactured through synthesis to ensure a consistent, predictable therapeutic profile.

The Therapeutic Function and Non-Sedating Type

The general therapeutic function of Loratine is the mitigation of discomfort stemming from histamine-mediated responses associated with allergic conditions. For example, it is typically used to provide support during periods of high allergen exposure. Loratadine is effective in counteracting these responses. This indicates the medicine provides relief from allergic discomfort by stabilizing the body's reaction to the released chemical.

A critical feature of Loratine is its categorization as a non-sedating antihistamine, which is a defining characteristic of its class. This non-drowsy attribute is achieved because the compound exhibits peripheral selectivity and does not readily penetrate the blood-brain barrier. This targeted peripheral action allows the medication to counteract the effects of histamine release without causing significant central nervous system depression or impaired cognitive function often observed with non-selective antihistamines.

Available Pharmaceutical Forms for Administration

The medicine Loratine is intended exclusively for oral administration, offering several convenient forms for patient use. The common pharmaceutical preparations include the standard tablet form, as well as an oral syrup and a rapidly-disintegrating tablet. These distinct forms offer flexibility for both adult and pediatric patient groups, accommodating varying ease of use requirements.

These oral forms ensure that the active ingredient is reliably delivered and absorbed through the gastrointestinal tract. Each preparation consists of the Loratadine active ingredient combined with pharmaceutical excipients appropriate for its stability and oral route, such as fillers for tablets or solvents for the syrup.

Therapeutic Uses of Loratine

What Loratine Treats: Main Uses and Benefits

Loratine is commonly used to help manage symptoms related to allergic processes, applied across domains where additional symptomatic support is needed and contributing to improved comfort during periods of heightened symptoms. The medication is applied across conditions presenting with episodic or fluctuating manifestations.

The primary therapeutic applications include managing Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis, and it is applied in addressing the symptoms of Chronic Idiopathic Urticaria (hives). It is relevant for easing symptoms that create noticeable functional strain, such as sneezing, runny nose, itchy/watery eyes, and skin itching. It generally helps support the patient during symptomatic episodes by contributing to easing the overall symptom load.

Its non-sedating profile may contribute to improved comfort during symptomatic periods without the common side effect of drowsiness. This may assist with maintaining functional stability and focus, which supports patients when symptoms interfere with routine daily activities.

Quick Fact: Relief for Allergic Symptoms

Symptom Domain	Key Symptom Focus	Context of Use
Upper Airway / Ocular	Sneezing, Itchy Eyes, Runny Nose	Seasonal and Year-Round Allergen Exposure
Dermatological	Pruritus, Wheals (Hives)	Recurrent or Persistent Skin Reactions

Regulatory References

National Institutes of Health

Eligibility and Restrictions for Use

The eligibility profile for Loratine is strictly defined by regulatory bodies to identify who can use the medicine and under which conditions.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in individuals with documented hypersensitivity to the active substance, Loratadine, or any of its formulation components. Furthermore, the medicine is not established for use in infants and children under 2 years of age, making this population ineligible according to government health authorities.

Age and Condition-Based Restrictions

Loratine is approved for use in adults and children 6 years of age and older. Use in children aged 2 to under 6 years is permitted only under restricted conditions, typically with specific liquid formulations, as not all dose forms are established for this group.

Patients with severe hepatic impairment or severe renal impairment (GFR less than 30 mL/min) require conditional use as officially documented. Reduced drug clearance in these populations necessitates a modified administration schedule. Additionally, individuals with Phenylketonuria (PKU) must avoid specific dosage forms containing phenylalanine.

Pregnancy and Lactation Status

Official regulatory documents state that use is preferable to avoid during pregnancy as a precautionary measure. Use is not recommended while breastfeeding, as the active substance is known to be excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Loratine is defined by its pharmacokinetic behavior and effects on specific diagnostic procedures, as documented in regulatory information.

Pharmacokinetic and Exposure Interactions

Loratine's metabolism occurs predominantly through Cytochrome P450 3A4 (CYP3A4) and to a lesser extent through CYP2D6. The co-administration of Loratine with known inhibitors of these hepatic enzymes is documented to result in substantially increased plasma concentrations of Loratadine. Specific medicines explicitly listed in regulatory documents as potentially causing this exposure increase include Ketoconazole, Erythromycin, and Cimetidine.

Interaction-Related Constraints

Constraint Type	Official Regulatory Statement
Diagnostic Test Interference	Must be discontinued for a minimum of 48 hours before the patient undergoes skin tests.
Food and Alcohol	Food ingestion is documented to increase Loratadine's AUC by approximately 48% and delay its absorption, without influencing the clinical effect. Co-administration with alcohol is formally documented as having no potentiating effects on psychomotor performance.
Population Consideration	Caution is noted for patients with severe liver impairment, as reduced clearance may occur, which alters systemic exposure.

Mechanism of Action

Loratadine acts through multiple biochemical mechanisms to modulate physiological responses. The active metabolite, desloratadine, is the primary compound mediating the drug's effects.

Selective H1-Receptor Antagonism

Loratadine primarily functions by selectively inhibiting peripheral histamine H1-receptors. By binding to this receptor and stabilizing its inactive conformation (inverse agonism), this interaction inhibits the binding and action of the endogenous mediator histamine. This antagonism decreases histamine-mediated signaling, thereby modulating subsequent activity within targeted pathways in the respiratory and vascular systems.

Modulation of Inflammatory Pathways

Beyond H1-receptor blockade, loratadine engages mechanisms that modulate downstream inflammatory signaling. The compound may modify early molecular steps by influencing the release profile of various chemical mediators (such as histamine and leukotrienes) from Fcepsilon RI^+ cells and mast cells. It may also influence the activation of key intracellular signaling sequences, such as the NF- kB pathway, thereby modulating the expression of pro-inflammatory factors.

Dosage and Administration Information

How to Use Loratine: Official Administration Guidelines

Loratine, which contains the active ingredient Loratadine, is designated exclusively for oral administration. It is available in standardized formulations, including tablets, oral syrup, and orally disintegrating tablets (ODT). The protocol for its use is characterized by a fixed schedule and strict dose limits.

Standard Dosing and Frequency

The standard adult dose (age 12 years and older) is 10 mg once daily, which also represents the maximum dose allowed within a 24-hour period. For children aged 2 to 5 years, the typical dose is 5 mg once daily, usually administered via the oral syrup or a 5 mg chewable formulation.

Contextual Use and Adjustments

Administration is generally permitted without regard to mealtime (with or without food). However, specific procedural steps exist for certain forms; for example, ODTs are placed on the tongue to dissolve and can be swallowed without water, while liquid forms require a calibrated measuring device for accuracy.

Dosage modification is required for patients with severely impaired organ function. For adults and children weighing more than 30 kg who have severe hepatic (liver) or renal (kidney) impairment, the recommended initial dose is typically 10 mg every other day to account for reduced clearance.

In terms of administrative constraints, it is specified that Loratine should be discontinued at least 48 hours prior to allergy skin testing to prevent interference with test results. If a dose is missed, the next dose should be taken as soon as remembered, but an individual should never take more than the single daily dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Loratine

Evidence for use in Seasonal Allergic Rhinitis (SAR)

Research exploring the use of Loratine for seasonal allergic rhinitis, commonly known as hay fever, includes Randomized Controlled Trials (RCTs). These short-term studies, often comparing the medicine to an inactive substance or to other similar medicines, were used in research exploring how symptoms change over time. The studies monitored patient-reported outcomes describing perceived discomfort, such as sneezing, itching of the eyes and nose, and runny nose, and also evaluated outcomes reflecting daily functioning or activity level.

The findings derived from these research efforts indicate patterns observed in the studies where participants reported various measurements of symptom intensity during the observed treatment periods. The evidence base contributes to understanding symptom patterns, and the overall body of controlled trials serves as the core evidence source for regulatory review.

However, certain research has explored short-term symptom changes and noted that findings were mixed when assessing specific individual symptoms, such as nasal congestion. While the main body of evidence focused on short-term changes, the long-term effects are not fully established and long-term outcomes are not well characterized, leaving a research gap for prolonged, continuous seasonal use.

Evidence for use in Perennial Allergic Rhinitis (PAR)

Research exploring the use of Loratine for year-round allergic rhinitis, a condition characterized by fluctuating or episodic manifestations throughout the year, includes controlled clinical trials. These studies were applied in research contexts involving fluctuating or unstable symptoms, evaluating outcomes related to physical discomfort. Researchers examined temporary physiological imbalance related to constant exposure to indoor allergens like dust mites.

The studies monitored how symptoms were reported in the observed populations, and the research provides context regarding short-term changes. The evidence contributes to the broader evidence landscape supporting the study of loratadine for conditions involving periods of heightened symptoms.

Evidence for use in Chronic Idiopathic Urticaria (CIU)

Research related to Chronic Idiopathic Urticaria, a condition where symptoms may vary in intensity and cause frequent functional limitations, has focused on measuring outcomes linked to inflammatory or irritative states. Studies exploring short-term symptom changes, typically lasting four to six weeks, were used in research examining symptom intensity or variability. Key outcomes measured were the severity of pruritus (itching) and the size and count of wheals (hives).

Research Gaps and Areas of Uncertainty

The research provides context but not individual predictions, and the evidence base, while extensive, presents certain gaps. The comparative evidence is lacking in terms of definitive, across-the-board findings compared to other medications in the same class, as certain studies reported mixed findings when focusing on specific symptoms like nasal congestion.

Specific data for certain groups remain insufficient. The follow-up durations were limited in many of the core efficacy trials, meaning that information about the sustained outcomes beyond four to six weeks is less detailed. Finally, the results apply only to the populations studied, and the evidence quality varies across studies, meaning that for many specific patient subgroups or complex circumstances, the research does not determine whether an individual will respond similarly.

Key Studies & References MedlinePlus Drug Information: Loratadine

Frequently Asked Questions (FAQ)

Common questions about Loratine (FAQ)

Q: How quickly does Loratine usually start working?

Regulatory documents state that the medicine's antihistaminic effects are generally noted to begin, often within 1 to 3 hours following oral administration.

This onset information is based on official data from the product’s safety and effectiveness studies.

Q: How long do the effects of Loratine last?

Loratine is formulated for once-daily use. The effects are documented in official information to last for 24 hours or more. The main active chemical in the body, known as the active metabolite, has a half-life of about 28 hours.

Q: Can Loratine be taken every day for a long time?

Guidelines in some regulatory regions note that clinical studies have supported continuous use for up to six months. Consultation with a health professional is generally recommended if use is necessary beyond that duration.

Q: Does Loratine interact with caffeine?

The official regulatory information about known drug-drug interactions does not generally list caffeine as a substance that significantly affects Loratadine's action or safety profile.

Q: Can Loratine affect sleep or cause insomnia?

Common side effects noted in official documents include drowsiness and nervousness. Less frequently, official side effect listings may include trouble sleeping or dizziness.

Q: Does Loratine interact with common pain relievers like ibuprofen?

Regulatory-based guidance suggests that Loratadine can generally be taken with common non-prescription pain relievers. This includes medicines such as paracetamol or ibuprofen.

Q: Is it okay to take Loratine with certain types of supplements?

Information regarding interactions with supplements and herbal remedies is often limited in regulatory texts. Caution is generally noted for any supplement that may cause drowsiness or dry mouth, as these effects can potentially be added to the medicine's known effects.

Q: Can Loratine be split or crushed, or must it be swallowed whole?

Administration instructions for the Orally Disintegrating Tablet (ODT) specifically state that it dissolves on the tongue. Instructions for the standard tablet form do not typically provide information about splitting or crushing.

Q: Is Loratine available without a prescription in most places?

The active ingredient in Loratine, loratadine, is widely classified as an over-the-counter (OTC) medicine in many regulatory regions. The specific classification, however, may vary by country or local region.

Q: Are headache or dizziness common side effects of Loratine?

Headache is classified as a Very Common side effect in official safety documents. While dizziness is sometimes listed in safety data, its frequency may be classified as less common, or its incidence is not known.

Q: Can Loratine be taken at any time of day?

Since the medicine is intended to be taken once daily and its effects last for a full 24 hours, regulatory instructions typically do not specify a required time of day. It may also be taken with or without food.

Q: Is Loratine safe for people with kidney disease?

Official warnings state that patients with severe kidney impairment may require a modified administration schedule due to the body's reduced ability to clear the drug. Official guidelines note that a healthcare professional should be consulted for specific use in the presence of kidney disease.

Q: Does the package insert for Loratine mention anything about driving or operating machinery?

Regulatory documents state that impairment of driving ability is not expected when the medicine is taken at the recommended dose. However, because some people may rarely experience drowsiness, official caution is noted regarding operating machinery or driving.

Q: What is the main benefit of Loratine compared to older allergy medicines?

Loratine is classified as a second-generation antihistamine. This classification is associated with the medicine's design to minimally penetrate the blood-brain barrier. This design is intended to reduce central nervous system effects, such as sedation, common to older antihistamines.

Q: How long until the full effect of Loratine is expected?

Official pharmacokinetic data indicates that the peak effect of the medicine is typically reached between 2.5 and 4 hours after administration. This reflects the time when the main concentration of the active ingredient is available in the body.

Q: Are there warnings about taking Loratine if you are taking heart medication?

The regulatory label notes that very rare but serious reactions have included cardiac effects, such as tachycardia (a rapid heart rate). Warnings concerning overdosage note a potential for increased heart-related adverse effects.

Q: Are there any known interactions between Loratine and herbal products?

Regulatory guidance indicates that comprehensive data on interactions with herbal remedies is limited. Caution is generally noted, especially for herbal products that may cause drowsiness or dry mouth.

Q: Can Loratine affect blood pressure?

Loratine at recommended doses does not typically affect blood pressure. However, regulatory information notes that cases of overdose have been associated with both elevated blood pressure and a rapid heart rate.

How should Loratine be stored and disposed of?

Official Storage and Disposal Requirements

Loratadine must be stored according to regulatory labeling to maintain its stability and effectiveness. The medication should be kept at controlled room temperature, generally between 2 C and 30 C (36 F and 86 F), unless otherwise specified. It is critical to protect the product from excessive moisture and humidity.

Handling and Packaging:

Original Container: Keep the medication in the original packaging, with containers tightly closed.
Child Safety: Always store Loratadine out of the reach and sight of children.

Disposal Rules:

Do not dispose of unused or expired Loratadine in household trash or by pouring it down a drain or toilet. Proper disposal is required to prevent environmental contamination, particularly to water sources. Medications must be disposed of in accordance with local, regional, and national regulations for pharmaceutical waste, often involving medication take-back programs.

Loratine